It is time to end our love affair with short-acting β 2 -agonists in asthma? Yes.

Published in: ERJ open research (2023)

Why not directly eradicate SABA from asthma management? The time to leave behind SABA in asthma management is now. We wasted enough time identifying the key issue in asthma morbidity and mortality. Please, eradicate SABA. https://bit.ly/3DU4mmo.

Keyphrases

chronic obstructive pulmonary disease
lung function
allergic rhinitis
cystic fibrosis